{"id":"W3189971813","doi":"10.1016/j.ejca.2021.05.040","title":"Phase I prognostic online (PIPO): A web tool to improve patient selection for oncology early phase clinical trials","year":2021,"lang":"en","type":"article","venue":"European Journal of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Foundation Medicine; Pharmacyclics; Chugai Pharmaceutical; Genentech; Sociedad Española de Oncología Médica; PharmaMar; European Society for Medical Oncology; Astellas Pharma; Eisai; Cancer Research UK; Seagen; Cilag; Puma Biotechnology; Arog Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Teva Pharmaceutical Industries; Les Laboratories Pierre Fabre; Regeneron Pharmaceuticals; Ipsen; Array BioPharma; Mersana Therapeutics; Exelixis; Karyopharm Therapeutics; Symphogen; Pfizer; Incyte; Grifols; F. Hoffmann-La Roche; Amgen; Deciphera Pharmaceuticals; Takeda Oncology; Halozyme; Sanofi; GlaxoSmithKline; Celgene; Daiichi Sankyo Europe; Servier; Bayer; AstraZeneca; Eli Lilly and Company; Samsung; Bristol-Myers Squibb","keywords":"Medicine; Cohort; Clinical endpoint; Oncology; Internal medicine; Confidence interval; Clinical trial; Surrogate endpoint","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.01807874,0.001377052,0.001297618,0.003310536,0.0002832378,0.002048764,0.001260295,0.0008608527,0.01961133],"category_scores_gemma":[0.06091437,0.000630806,0.0009558275,0.001895968,0.0002599115,0.001851762,0.002085665,0.001444723,0.005842336],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00056453,"about_ca_system_score_gemma":0.001949707,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003971489,"about_ca_topic_score_gemma":0.0005690772,"domain_scores_codex":[0.9951682,0.002950898,0.0006052968,0.0004852653,0.0006534428,0.0001369255],"domain_scores_gemma":[0.9405465,0.04591129,0.006116129,0.002558164,0.00288509,0.001982752],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007844199,0.001091961,0.09705317,0.002116539,0.0007537717,0.0003944748,0.0003471748,0.01059205,0.001758115,0.002661404,0.2034565,0.6719307],"study_design_scores_gemma":[0.01360851,0.004733963,0.1340039,0.001893964,0.001750139,0.002616076,0.0003416581,0.4975301,0.01571863,0.03092702,0.2963212,0.0005547991],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"methods","genre_gemma":"software","genre_scores_codex":[0.1498353,0.005005064,0.4737006,0.01262577,0.001257058,0.01192518,0.08813453,0.2314848,0.02603167],"genre_scores_gemma":[0.4808915,0.002234141,0.4268067,0.004480321,0.001077641,0.0159469,0.05496464,0.007503076,0.00609525],"genre_candidate":"software","genre_consensus":null,"teacher_disagreement_score":0.01961133,"threshold_uncertainty_score":0.09561068,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1061919721028062,"score_gpt":0.4763975619444084,"score_spread":0.3702055898416022,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}